Piper Sandler Has Lowered Expectations for CVS Health (NYSE:CVS) Stock Price

CVS Health (NYSE:CVS) had its price target reduced by Piper Sandler from $101.00 to $99.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the pharmacy operator’s stock. Piper Sandler’s price target would indicate a potential upside of 36.58% from the company’s current price.

Several other research firms have also weighed in on CVS. Morgan Stanley lifted their price objective on shares of CVS Health from $89.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Wolfe Research cut their target price on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. JPMorgan Chase & Co. lifted their price objective on CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of CVS Health in a report on Monday, December 29th. Finally, Leerink Partners restated an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. Twenty investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.95.

CVS Health Trading Up 0.9%

NYSE CVS opened at $72.49 on Tuesday. CVS Health has a 12 month low of $58.35 and a 12 month high of $85.15. The stock has a 50-day simple moving average of $76.11 and a 200 day simple moving average of $77.70. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $92.22 billion, a PE ratio of 52.53, a P/E/G ratio of 0.75 and a beta of 0.51.

CVS Health (NYSE:CVS) last issued its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company’s revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Research analysts forecast that CVS Health will post 5.89 EPS for the current year.

Hedge Funds Weigh In On CVS Health

Several hedge funds have recently made changes to their positions in the business. National Pension Service increased its position in shares of CVS Health by 3.1% during the 3rd quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock worth $301,532,000 after purchasing an additional 119,189 shares during the last quarter. Kingsview Wealth Management LLC boosted its holdings in shares of CVS Health by 316.2% in the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after buying an additional 79,340 shares during the last quarter. AE Wealth Management LLC boosted its holdings in shares of CVS Health by 6.2% in the 3rd quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock valued at $19,391,000 after buying an additional 14,983 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of CVS Health by 11.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock valued at $16,971,000 after buying an additional 22,653 shares in the last quarter. Finally, Alpha Omega Wealth Management LLC increased its holdings in CVS Health by 12.3% during the third quarter. Alpha Omega Wealth Management LLC now owns 149,902 shares of the pharmacy operator’s stock worth $11,301,000 after buying an additional 16,418 shares during the last quarter. 80.66% of the stock is owned by institutional investors.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is accelerating a roll‑out of small, pharmacy‑only stores (about 20 planned this year) designed to focus on prescriptions and pharmacist services — a move that could improve margins and serve underserved neighborhoods. CVS Accelerates Rollout of New Pharmacy-Only Store Format
• Positive Sentiment: Company plans to open substantially more locations in 2026 (reports cite roughly 60 new openings after years of net closures), signaling a strategic pivot to grow retail pharmacy revenues and refill volumes. CVS plans to open 60 new stores in 2026 after years of closures
• Positive Sentiment: Unusually large call‑option buying was noted recently (over 30k calls traded), a short‑term bullish signal that can lift near‑term share demand. CVS Health (CVS) Increases Yet Falls Behind Market: What Investors Need to Know
• Positive Sentiment: Analyst coverage remains largely bullish — consensus implies meaningful upside and the majority of sell‑side ratings are positive, supporting investor confidence despite some near‑term headwinds. CVS Health (CVS) Under Analyst Spotlight Following Proposed FTC Settlement Related to Insuling Pricing
• Neutral Sentiment: Omnicare (CVS subsidiary) advanced a court‑supervised sale process and entered an asset purchase agreement with GenieRx, which could simplify the portfolio and free cash but may take time to realize value. Omnicare Advances Court-Supervised Process While Continuing to Deliver Enhanced Value to Customers
• Neutral Sentiment: Piper Sandler trimmed its price target slightly (from $101 to $99) but maintained an overweight rating — a modest tweak that leaves substantial upside in many analysts’ models. Benzinga piece on Piper Sandler price target change
• Negative Sentiment: Regulatory/legal risk remains in focus — coverage has flagged a proposed FTC settlement related to insulin pricing that could create uncertainty or financial exposure depending on final terms. CVS Health (CVS) Under Analyst Spotlight Following Proposed FTC Settlement Related to Insuling Pricing

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.